Board of Directors
Chairman of the Board
Mr. Scott L. Glenn serves as the Chairman of the Board for ALASTIN Skincare®, Chairman of the Board for Tokalas Inc., and Managing Director and Founder of Windamere Venture Partners, LLC. He was the first venture investor in SkinMedica® in 2001 via Windamere Ventures. He began his career at Allergan, Inc., finishing as Division General Manager. Since then, and for more than 25 years, Mr. Glenn has founded over twenty successful biotech companies including Quidel Corp., Exagen Diagnostics, Inc., Cadence Pharmaceuticals, Prometheus Laboratories, Santaurus, Inc., NovaCardia, DexCom, SpineWave and Conception Technologies, Inc.
Diane S. Goostree
Ms. Goostree has 30 years of experience in the pharmaceutical and cosmeceutical industries. She was a key executive building SkinMedica® from 2002 onward. Prior to her appointment as CEO of ALASTIN Skincare®, she was the CEO of Intrepid Therapeutics, Inc., developing new molecules for prescription dermatology products. Her background includes experience in business development, R&D, sales and marketing, manufacturing, and general management. Ms. Goostree’s career successes have included significant capital raises, obtaining FDA approval for products and medical devices, and taking a company public. Ms. Goostree holds a B.S. in Chemical Engineering from the University of Kansas and earned her MBA from the University of Missouri at Kansas City.
Mr. Garner is a pharmaceutical executive with over 40 years of diverse experience in the healthcare industry ranging from diagnostics and devices to pharmaceuticals. He was part of the senior management team that built Hybritech, Inc. After facilitating the acquisition of Dura Pharmaceuticals, Inc. in 1989 for $5 million, Mr. Garner served as Chief Executive Officer and Chairman until the company was sold in November 2000, for $1.8 billion to Elan Corporation. In addition, Mr. Garner has founded or co-founded numerous specialty pharmaceutical companies in San Diego including Cadence Pharmaceuticals, Inc., DJ Pharma, Elevation Pharmaceuticals, Evoke Pharma, Kalyra Pharmaceuticals, Inc., Meritage Pharma, SkinMedica®, Xcel Pharmaceuticals, Inc., Zavante Therapeutics, Inc. and Zogenix, Inc.
Mark G. Rubin, M.D.
Dr. Rubin is a board certified dermatologist whose private practice, The Lasky Skin Center in Beverly Hills, is dedicated exclusively to Cosmetic Dermatology. He also maintains his position as Assistant Clinical Professor of Dermatology at the University of California, San Diego. Dr. Rubin is a specialist in skin rejuvenation and has written numerous papers, book chapters and a textbook on skin rejuvenation. He is an international lecturer and a well-known leader in research related to the science of rejuvenating skin treatments.
Ms. Salo is a highly successful executive and recognized leader in the skincare and facial aesthetics industry. During her 27 years with Allergan, Inc. she held the position of Vice President, Sales and Marketing, for the US Facial Aesthetics, Plastic Surgery, Urological and Neurosciences divisions. Products in her area of responsibility included BOTOX® therapeutic for neurological applications, breast implants, VOLUMA® and JUVEDERM® for facial volumizing and BOTOX® Cosmetic for facial aesthetics. During her leadership, Allergan, Inc. held a 78% market share in the botulinum toxin cosmetic market, VOLUMA® achieved revenues in excess of $100 million in the first year of sales, and the aesthetics business grew from $600M to $1B in three years.
Mr. Schwarz has dedicated more than 20 years of his career to the specialty of dermatology, in both the medical and aesthetics fields. He was President of SkinMedica® from 2010 until its acquisition by Allergan, Inc. Under his leadership, aesthetic skin care revenues delivered a compounded annual growth rate of more than 35 percent. Previously, he served as Vice President of Sales for La Roche-Posay, a division of L'Oreal. Prior to that, he was the Global Strategic Marketing and Business Development Manager at Galderma International, France, after more than 10 years in managerial and sales positions with the company.
Mr. LaRue currently serves as an independent board member and chair of the audit committee for multiple public and private companies in the life sciences industry. He has extensive corporate, strategic and operational experience and served as Senior Vice President and Chief Financial at Cadence Pharmaceuticals, Inc., a biopharmaceuticals company, until the company's $1.4 billion acquisition by Mallinckrodt plc in March 2014. Prior to joining Cadence, Mr. LaRue served as the Senior Vice President and Chief Financial Officer of CancerVax Corporation, a biotechnology company, from 2001 until its merger with Micromet, Inc. in May 2006. Mr. LaRue received a B.S. in business administration and an M.B.A. from the University of Southern California.
Ms. Sandoval holds a proven track record of successful business leadership and development of leading brands in a variety of areas including the medical aesthetics arena. She currently serves as Chief Commercial Officer for Alder Biopharmaceuticals, and previously was Chief Commercial Officer at Kythera Biopharmaceuticals, which was sold to Allergan in 2015 for $2.1 Billion. Prior to this, Ms. Sandoval spent 24 years at Allergan Inc., where she held the role of Vice President, Global Strategic Marketing, and drove the launch of the market-leading Juvederm® dermal filler and established its worldwide marketing team.